Good_老虎社区_美港股上老虎

QSL
2021-12-26

Good

Japan health panel approves Merck's oral COVID-19 treatment

TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COV

Japan health panel approves Merck's oral COVID-19 treatment

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":698524046,"tweetId":"698524046","gmtCreate":1640474894074,"gmtModify":1640474894297,"author":{"id":3586036183115498,"authorId":3586036183115498,"authorIdStr":"3586036183115498","name":"QSL","avatar":"https://static.tigerbbs.com/bb5d27e2d0cb86c5c558fecd085ec01e","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good</p></body></html>","htmlText":"<html><head></head><body><p>Good</p></body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/698524046","repostId":2193127176,"repostType":4,"repost":{"id":"2193127176","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640345481,"share":"https://www.laohu8.com/m/news/2193127176?lang=&edition=full","pubTime":"2021-12-24 19:31","market":"us","language":"en","title":"Japan health panel approves Merck's oral COVID-19 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2193127176","media":"Reuters","summary":"TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COV","content":"<p>TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COVID-19 antiviral pill developed by Merck &amp; Co Inc , part of plans by Prime Minister Fumio Kishida to roll out new treatments by yearend as concerns rise about the Omicron variant.</p>\n<p>The panel decision sets the stage for shipments of 200,000 doses across the country from this weekend, based on preparations announced earlier by Kishida.</p>\n<p>Japan is betting heavily on oral treatments to keep serious infections and deaths at bay should a feared sixth wave of the pandemic emerge. The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir.</p>\n<p>In addition, Kishida announced last week a deal to procure 2 million doses of a separate antiviral pill&nbsp;developed by Pfizer Inc. And Japan's Shionogi &amp; Co is expected to soon file for approval of its own treatment&nbsp;supplying another 1 million doses by early next year.</p>\n<p>U.S. regulators on Thursday authorized the Merck pill for certain high-risk adult patients.</p>\n<p>Countries rushed to buy Merck's molnupiravir after very promising initial results, but subsequent company data in late November indicated the drug was markedly less effective than previously thought. France cancelled its order on Wednesday.</p>\n<p>Japan this week confirmed the first known cases of Omicron infections that could not be traced back to overseas travelers. Community transmissions of the variant have now been found in the western cities of Osaka and Kyoto, and a suspected case was announced in Tokyo on Friday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Japan health panel approves Merck's oral COVID-19 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJapan health panel approves Merck's oral COVID-19 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-24 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COVID-19 antiviral pill developed by Merck &amp; Co Inc , part of plans by Prime Minister Fumio Kishida to roll out new treatments by yearend as concerns rise about the Omicron variant.</p>\n<p>The panel decision sets the stage for shipments of 200,000 doses across the country from this weekend, based on preparations announced earlier by Kishida.</p>\n<p>Japan is betting heavily on oral treatments to keep serious infections and deaths at bay should a feared sixth wave of the pandemic emerge. The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir.</p>\n<p>In addition, Kishida announced last week a deal to procure 2 million doses of a separate antiviral pill&nbsp;developed by Pfizer Inc. And Japan's Shionogi &amp; Co is expected to soon file for approval of its own treatment&nbsp;supplying another 1 million doses by early next year.</p>\n<p>U.S. regulators on Thursday authorized the Merck pill for certain high-risk adult patients.</p>\n<p>Countries rushed to buy Merck's molnupiravir after very promising initial results, but subsequent company data in late November indicated the drug was markedly less effective than previously thought. France cancelled its order on Wednesday.</p>\n<p>Japan this week confirmed the first known cases of Omicron infections that could not be traced back to overseas travelers. Community transmissions of the variant have now been found in the western cities of Osaka and Kyoto, and a suspected case was announced in Tokyo on Friday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","MRK":"默沙东","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4516":"特朗普概念","BK4007":"制药","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193127176","content_text":"TOKYO, Dec 24 (Reuters) - A Japanese health ministry panel on Friday recommended approval of the COVID-19 antiviral pill developed by Merck & Co Inc , part of plans by Prime Minister Fumio Kishida to roll out new treatments by yearend as concerns rise about the Omicron variant.\nThe panel decision sets the stage for shipments of 200,000 doses across the country from this weekend, based on preparations announced earlier by Kishida.\nJapan is betting heavily on oral treatments to keep serious infections and deaths at bay should a feared sixth wave of the pandemic emerge. The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir.\nIn addition, Kishida announced last week a deal to procure 2 million doses of a separate antiviral pill developed by Pfizer Inc. And Japan's Shionogi & Co is expected to soon file for approval of its own treatment supplying another 1 million doses by early next year.\nU.S. regulators on Thursday authorized the Merck pill for certain high-risk adult patients.\nCountries rushed to buy Merck's molnupiravir after very promising initial results, but subsequent company data in late November indicated the drug was markedly less effective than previously thought. France cancelled its order on Wednesday.\nJapan this week confirmed the first known cases of Omicron infections that could not be traced back to overseas travelers. Community transmissions of the variant have now been found in the western cities of Osaka and Kyoto, and a suspected case was announced in Tokyo on Friday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":515,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}